Clinical trial
Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer
NCT00040170 · Transgene, Industry · Terminated
Key facts
| NCT number | NCT00040170 |
|---|---|
| Title | Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer |
| Official title | Randomized Multicenter Phase II Study Evaluating Two Dosing Schedules of TG4010(MVA-MUC1-IL2) in Patients With Adenocarcinoma of the Prostate |
| Lead sponsor | Transgene, Industry |
| Collaborators | University of California, Los Angeles The Cleveland Clinic University of Arizona |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Biological |
| Interventions | MVA-MUC1-IL2 |
| Enrollment | 50 |
| Start date | May 1, 2002 |
| First posted | Jun 25, 2002 |
| Last update posted | Nov 2, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: